Entrada Therapeutics, Inc.

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

Vertex Pharmaceuticals reported third quarter revenue that exceeded expectations and raised its full-year guidance as a result, which analysts described as a typical quarter for the company. What gene

Alumis, Inc. planned to raise between $282.4m and $317.7m in the last biopharmaceutical initial public offering in the US during the first half of 2024, but instead grossed $250m on 27 June from the

“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning